Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer - Bertin Instruments

    Scientific publications

    Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

    Elizabeth Buck1, Prafulla C. Gokhale3, Susan Koujak1, Eric Brown3, Alexandra Eyzaguirre1, Nianjun Tao4, Maryland Rosenfeld-Franklin3, Lorena Lerner4, M. Isabel Chiu4, Robert Wild3, David Epstein2, Jonathan A. Pachter2 and Mark R. Miglarese1
    Sources: 1Translational Research and 2Cancer Biology, OSI Pharmaceuticals, Farmingdale, New York; 3In Vivo Pharmacology,, OSI Pharmaceuticals, Boulder, Colorado; and 4Biology, AVEO Pharmaceuticals, Cambridge, Massachusetts
    Published OnlineFirst October 5, 2010; Molecular Cancer Therapeuticsdoi: 10.1158/15Life Sciences-7163.MCT-10-0Cryolys cooling option

    Sample name

    Human tissues

    ANY QUESTIONS? CONTACT AN EXPERT

    Please fill in this form if you wish to contact our sales team or receive further information.

    My Account
    Forgot password ?

    Add a question !

    Add a question